In a nutshell This article investigated the safety and effectiveness of Lutetium-177 PSMA (LuPSMA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The authors concluded that LuPSMA is a safe and effective treatment option for these patients. Some background mCRPC is cancer which has spread from its original site...
Read MoreCurrent PSA level-20 or above Posts on Medivizor
Looking for patients with recurrent prostate cancer to test nivolumab
In a nutshell This phase 2 trial will investigate the safety and effectiveness of nivolumab (Opdivo) in recurrent prostate cancer (PC). The main outcome will be disease control. This trial is recruiting at two locations in Boston, MA, US. The details Prostate cancer (PC) is a highly treatable cancer in men. Patients are usually...
Read MoreLooking for men with prostate cancer to test chemotherapy in combination with radiotherapy
In a nutshell This trial evaluates the effectiveness of using chemotherapy in combination with radium-223 (a type of internal radiotherapy). The main outcome to be measured is overall survival. This trial is taking place in the United States. The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...
Read MoreComparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer
In a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...
Read MoreRadiotherapy treatments for patients with prostate cancer
This study compared the outcome of low-dose rate brachytherapy (LDR-BT) and image-guided intensity-modulated radiotherapy (IG-IMRT) for different severities of localized prostate cancer. Five year survival rates will almost the same across both treatments. Five year biochemical failure free survival rates were higher for patients treated with LDR-BT...
Read MoreTreatments available for advanced, hormone-resistant prostate cancer
In a nutshell The authors aimed to determine guidelines for the treatment of relapsing, metastatic, and hormone-resistant prostate cancer. Some background Metastatic prostate cancer (advanced cancer) is cancer that has spread outside of the prostate to other organs of the body, despite treatment. Hormone therapy is the standard...
Read MoreHormone therapy during or after radiation therapy increases the risk of cardiovascular events
In a nutshell This study examined the effect of androgen deprivation therapy (ADT) on the risk of cardiovascular events (such as stroke or heart attack) in men treated with radiation therapy. Researchers concluded that ADT use during or after radiation therapy increases the risk of cardiovascular events. Some background Radiation therapy is a...
Read MoreExamining surgery as a primary treatment for high-risk prostate cancer
In a nutshell This study examined evidence for the role of prostate surgery in treating high-risk prostate cancer. Authors concluded that surgery is an effective primary treatment option for men with high-risk disease. Some background Localized prostate cancer is cancer that is confined to the prostate gland. Men with high-risk localized prostate...
Read MoreShould immunotherapy be administered before or after hormone therapy?
In a nutshell This study examined whether immunotherapy with sipuleucel-T (Provenge) shows a greater immune response if administered before or after androgen deprivation therapy (ADT). Authors present preliminary evidence of improved immune cell response when sipuleucel-T was administered first in patients with recurrent prostate cancer at high risk of...
Read MoreAn Overview of Hormonal Therapy Options for Advanced Prostate Cancer
How does prostate cancer work? With Andrew Schorr as host, Dr. Russell Szmulewitz of the University of Chicago Medical Center gives a short description of the endocrinology of prostate cancer and provides an overview of hormonal therapies. Listen as Dr. Szmulewitz examines the changing treatment paradigm including risks and...
Read MoreManagement of high-risk prostate cancer – a summary of findings
In a nutshell This review evaluated recent evidence on the management of high-risk prostate cancer. Primary treatment options for high-risk prostate cancer were generally associated with good effectiveness, but authors advised that risk assessment is in need of refinement and standardization. Some background About 15% of men with prostate cancer...
Read MoreApalutamide: Early results of a new type of secondary hormone therapy
In a nutshell This study examined the benefit of adding apalutamide (JNJ 56021927) to standard hormone therapy in men with castration-resistant prostate cancer (CRPC). Researchers reported preliminary evidence for apalutamide as a safe and effective additional hormone therapy for high-risk CRPC. Some background Hormone therapy is the standard of...
Read More
